# AbbVie

AbbVie’s $11 Billion Gambit: Securing the Future of Immunology Beyond the Humira Cliff

AbbVie has entered an agreement to acquire Apogee Therapeutics for $10.9 billion to bolster its immunology portfolio. The deal focuses on zumilokibart, a next-generation treatment for inflammatory diseases that offers significantly less frequent dosing than current market leaders.

NeTe2026年6月22日 18:38

#AbbVie#Apogee Therapeutics#Immunology

Close-up of a scientist's hand in glove conducting an experiment with petri dishes and colorful liquids in a lab.

Business

AbbVie Taps Chinese Innovation in $745 Million Bet on Next-Generation Pain Relief

Haisco Pharmaceutical has signed a global licensing deal with AbbVie for its Nav1.8 pain inhibitor, worth up to $745 million. The agreement grants AbbVie exclusive rights outside of Greater China and highlights the shift toward Chinese-developed innovative therapies in the global market.

NeTe2026年4月12日 08:28

#Haisco Pharmaceutical#AbbVie#Biotech